Thomas A. Abrams

Thomas A. Abrams, MD, is an Assistant Professor of Medicine at Harvard Medical School and a practicing Medical Oncologist at the Dana-Farber Cancer Institute. He specializes in gastrointestinal cancers and is affiliated with the Gastrointestinal Cancer Center, providing clinical care at both the Boston and Chestnut Hill locations of Dana-Farber.

• Institution: Dana-Farber Cancer Institute
• Academic Affiliation: Harvard Medical School
• Department: Medical Oncology/Solid Tumor Oncology
• Specialty: Gastrointestinal Cancers

Dr. Abrams completed his medical training at Jefferson Medical College in 2000, followed by residency and fellowship in Internal Medicine and Hematology & Oncology at the University of Michigan Hospitals and Health Centers. He is board certified in Medical Oncology (2006).

His clinical and research interests focus on gastrointestinal malignancies, including pancreatic, colorectal, liver, biliary, esophageal, gastric, anal, and neuroendocrine tumors. He is actively involved in advancing treatment strategies for solid tumors, particularly through clinical care and translational research within the Medical Oncology division at Dana-Farber.

While no specific publications or research articles are listed in the provided text, his work appears to be centered on improving outcomes in gastrointestinal oncology, with a strong emphasis on patient-centered care and innovative therapeutic approaches.

Dr. Abrams has received high patient ratings, with numerous testimonials praising his compassion, expertise, and dedication as a caregiver.

He has not listed any formal scientific awards or mentoring activities in the available information. There is no indication of part-time status, suggesting a full-time academic and clinical role. He supports research initiatives at Dana-Farber, though specific grants or funding sources are not detailed.

Dr. Abrams is part of a multidisciplinary team within the Gastrointestinal Cancer Program at Dana-Farber, collaborating with researchers, clinicians, and support staff to deliver comprehensive cancer care and advance clinical research in solid tumors.